eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2021
vol. 7
 
Share:
Send email
Share:
abstract:
Original paper

FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study

Roberto Catanzaro
1
,
Alice Aleo
1
,
Morena Sciuto
1
,
Luca Zanoli
2
,
Baskar Balakrishnan
3
,
Francesco Marotta
4

  1. Department of Clinical and Experimental Medicine – Gastroenterology Section, “Gaspare Rodolico” Policlinico Hospital, University of Catania, Catania, Italy
  2. Department of Clinical and Experimental Medicine, “Gaspare Rodolico” Policlinico Hospital, University of Catania, Catania, Italy
  3. Mayo Clinic, Rochester, MN, USA
  4. ReGenera R&D International for Aging Intervention, Milano, Italy
Clin Exp HEPATOL 2021; 7, 1: 111-116
DOI: https://doi.org/10.5114/ceh.2021.104543
Online publish date: 2021/03/25
View full text Get citation
 
PlumX metrics:
Aim of the study
Hepatitis C virus (HCV) can cause a chronic liver infection which could then develop into fibrosis, cirrhosis, and hepatocellular carcinoma. Today the diagnosis of liver fibrosis also includes the use of biomarkers. The purpose of our study was to determine the ability of the fibrosis index based on four factors (FIB-4) and aspartate aminotransferase-to-platelet ratio (APRI) to predict the severity of liver fibrosis or cirrhosis.

Material and methods
Medical records of 106 patients with HCV-related liver fibrosis were analyzed. All patients underwent clinical examination, blood tests (complete blood count, total bilirubin, etc.) and transient elastography. FIB-4 and APRI were calculated for each patient.

Results
Twenty-six patients (24.52%) had F4 fibrosis, 80 patients (75.48%) had non-F4 fibrosis (F0-F3). There was a statistically significant difference (p < 0.05) between non-F4 fibrosis patients and F4 fibrosis patients in many parameters, including APRI (F4 fibrosis patients had higher values: 2.06 ±3.22 compared to 0.68 ±0.76 of the non-F4 group; p = 0.044) and FIB-4 (F4 fibrosis patients had higher values: 4.84 ±4.14 compared to 2.29 ±2.90 of the non-F4 group; p = 0.006). Receiver operating characteristic (ROC) curve analysis for APRI and FIB-4 revealed that the area under the curve (AUC) of FIB-4 was 0.855 (CI: 0.813-0.936), while the APRI score had an AUC of 0.767 (CI: 0.79-0.932).

Conclusions
In this study, patients with severe fibrosis or cirrhosis were found to have a higher FIB-4 value than APRI in the context of chronic hepatitis C.

keywords:

liver fibrosis, biomarkers, hepatitis C virus, FIB-4, APRI
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.